Biote : Investor Presentation

Transforming Healthy Aging

2

Transforming Healthy Aging

Forward-LookingStatements

Forward-Looking Statements

Certain statements in this Presentation may be considered "forward-looking statements" within the meaning of the provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events of BioTE Holdings, LLC's ("BioTE" or the "Company") future financial or operating performance. For example, projections of future revenue and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "can," "should," "will," "estimate," "plan," "project," "forecast," "intend," "expect," "hope," "anticipate," "believe," "seek," "target," "continue," "could," "might," "ongoing," "potential," "predict," "would," or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about our business and our industry, and are not guarantees of our future performance. These statements are subject to a number of known and unknown risks, uncertainties, and other factors, many of which are beyond ability to control or predict, which may cause actual results to differ materially from those expressed or implied herein, including, but not limited to: the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers' reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers' sensitive to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; our limited operating history; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors; future exchange and interest rates; and other risks and uncertainties indicated in the section captioned "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the United States Securities Exchange Commission ("SEC") on March 15, 2024 and any other materials subsequently filed or furnished with the SEC.

These forward-looking statements are based upon estimates and assumptions that are inherently uncertain. Nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward- looking statements will be achieved. You are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements contained in this release, whether as a result of new information, future events or otherwise, except as required by applicable law.

Financial Information; Non-GAAP Financial Measures

This Presentation includes certain financial measures not presented in accordance with generally accepted accounting principles ("GAAP") including, but not limited to, EBITDA and EBITDA Margin. These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing the Company's financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under GAAP. You should be aware that the presentation of these measures may not be comparable to similarly-titled measures used by other companies. A reconciliation of these measures to the most directly comparable GAAP measure is included in the appendix to these slides on pages 21-22.

The Company believes these non-GAAP measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in and in comparing its financial results with other similar companies, many of which present similar non-GAAP financial measures to investors. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures.

This Presentation also includes certain projections of non-GAAP financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable GAAP measures is included and no reconciliation of the forward-lookingnon-GAAP financial measures is included.

Certain monetary amounts, percentages and other figures included in this Presentation have been subject to rounding adjustments. Certain other amounts that appear in this Presentation may not sum due to rounding.

Use of Projections

This Presentation contains financial forecasts with respect to the Company's projected financial results for the fiscal year ended December 31, 2024, including Revenue and, Adjusted EBITDA and EBITDA Margin. The Company's independent auditor has not audited, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, it did not express an opinion or provide any other form of assurance with respect thereto for the purpose of this Presentation. These projections should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Accordingly, there can be no assurance that the prospective results are indicative of the future performance of the Company or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved.

Industry and Market Data

This Presentation includes certain information and statistics obtained from third-party sources. The Company has not independently verified the accuracy or completeness of any such third-party information.

No Offer

This Presentation shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Biote, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Transforming Healthy Aging

Looking Forward

Biote offers an evidence-based, individualized, and comprehensive approach to healthcare

3

Our Vision

To be a part of everyone's routine

healthcare as they age

4

Transforming Healthy Aging

Biote by the Numbers1

The Established Leader in Hormone Optimization

$185M

2023 Revenue

$55M2

2023 Adj. EBITDA

~30%2

2023 Adj. EBITDA

Margin

7,100+

Biote-Certified

Practitioners

~4M

Procedures

Performed

~400,000

Active Patients

1. All information as of December 31, 2023 unless otherwise stated. 2. Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial figures. Please see slides

21-22 for a reconciliation of these measures to their most closely comparable GAAP measures.

5

Transforming Healthy Aging

Investment Highlights

Trusted Leader in	Large & Growing	Proprietary	Growing, Profitable
Technology,
Hormone	Addressable	& Capital-light
Clinical, Education
Optimization	Markets	Business Model
& Training Platform

Becoming the Leading Single-Source Provider of Evidence-Based Therapeutic Wellness Solutions

Transforming Healthy Aging

Why Hormone Optimization

Hormone Deficiency Impacts Quality of Life and Heightens Risk of Chronic Disease

Common	Hormone deficiency
symptoms:(1)	increases risk of:
•	Low energy	•	Heart disease(2)(3)
•	Insomnia	•	Breast cancer(4)(5)
•	Decreased libido	•	Osteoporosis(6)
•	Brain fog	•	Neurodegenerative
•	Irritability		diseases(7)

• Depression
• Hot flashes/sweats
• Bladder problems

6

~47M Women

affected with menopausal symptoms(8)

~20M Men

over age 45 are affected by low testosterone(9)

7

Transforming Healthy Aging

Biote: A Better Solution for Practitioners & Patients

Network of 7,100+ certified practitioners1

• OB/GYN
• Family Practice/Internal Medicine
• Urology
• Functional Medicine
• Nurse Practitioners

Our Practitioner Certification Process is

rigorous, involving pre-screening, an intensive two-day training program, and continuous education and evaluation in practice

Biote-certified practitioners customize treatment therapies based on our

proprietary algorithms to meet each

patient's unique needs and preferences

Our proprietary technology empowers practitioners with a single-source platform, exclusive software solutions and strategic marketing support

1. As of December 31, 2023.

8

Transforming Healthy Aging

Nutraceuticals Complement

Our Hormone Therapy Offerings

• Biote-brandeddietary supplements and cosmeceuticals
• Complementary to procedures performed by Biote-certified practitioners
• Nutraceuticals strengthen the patient connection to Biote and enhance practitioner economics

9

Transforming Healthy Aging

A More Proactive and Holistic

Approach to Healthcare

Practitioners Seek:

• Single-sourcetechnology platform
• Therapies to address common health conditions
• Revenue opportunities that enhance clinic economics

Patients Seek:

• Ease and convenience from a single provider
• Evidence-basedresults
• Broad range of complementary wellness

therapies

Transforming Healthy Aging

BioteRx: New Therapeutic Wellness Offerings from a Trusted Network of Providers

Wellness Categories

Hormone Optimization

Weight Loss/	Thyroid
Body Composition	Health
Sexual	Preventive
Health	Wellness
Hair Loss/

Aesthetic Dermatology